Panatuss PED and Xarelto

• Generic Name: chlophedianol / dexchlorpheniramine / pseudoephedrine
• Dosage Forms: n.a.
• Other Brand Names: Panatuss PED, Vanacof, Panatuss PED Drops

Chlophedianol is a cough suppressant. It affects the signals in the brain that trigger cough reflex.

Dexchlorpheniramine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Panatuss PED is a combination medicine used to treat runny or stuffy nose, sneezing, itching, watery eyes, cough, and sinus congestion caused by allergies, the common cold, or the flu.

Panatuss PED will not treat a cough that is caused by smoking, asthma, bronchitis, or emphysema.

Panatuss PED may also be used for purposes not listed in this medication guide.

• Generic Name: rivaroxaban
• Dosage Forms: tablet, film coated
• Other Brand Names: Xarelto, Xarelto Starter Pack

Xarelto (rivaroxaban) blocks the activity of certain clotting substances in the blood.

Xarelto is used to prevent or treat a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism). A DVT can occur after knee or hip replacement surgery, and during or after a stay in the hospital when you cannot move around as much as normal.

Xarelto is sometimes used to lower your risk of a DVT or PE coming back after you have received treatment for blood clots for at least 6 months.

Xarelto is used in people with atrial fibrillation (a heart rhythm disorder) to lower the risk of stroke caused by a blood clot.

Xarelto is used to help prevent blood clots in certain people hospitalized for an acute illness who are at risk of getting blood clots and who do not have a high risk of bleeding.

Xarelto is also given together with aspirin to lower the risk of stroke, heart attack, or other serious heart problems in people with coronary artery disease (decreased blood flow to the heart) or peripheral artery disease (decreased blood flow to the legs).